Featured
Kohler Wisconsin Redefines Wellness Retreats with Integrated Design
Clinic Moves Sep 26, 2026
Trial Briefs Sep 25, 2026
Vaccine News Sep 24, 2026
Kohler Wisconsin redefines wellness retreats with integrated design, blending movement, recovery, and architecture into a...
FDA reviews two novel ADHD drug candidates in late-stage development, offering new approaches to treatment.
Zorevunersen dravet patients showed adaptive gains over two years, surpassing standard antiseizure therapy in a...
Read our latest Drug Approvals articles.
Doctors reject federal vaccine changes lacking scientific backing as top medical groups like AAP and...
Vonoprazan significantly reduces nighttime reflux symptoms in patients with NERD, offering a promising new treatment...
GammaTile slows brain tumor regrowth in glioblastoma patients with promising results from the GESTALT trial...
Study reveals combined risk factors significantly increase late-onset Parkinson disease risk, with multiple exposures showing synergistic effects beyond individ
Study reveals combined risk factors significantly increase late-onset Parkinson disease risk, with multiple exposures showing synergistic effects beyond individ
GammaTile slows brain tumor regrowth in glioblastoma patients with promising results from the GESTALT trial period.
Discover the latest stroke rehabilitation guidelines from American Heart Association for improved recovery outcomes with updated recommendations.
FDA approves Oveporexton (Orzeyful) for Type 1 Narcolepsy, first therapy to restore orexin signaling. Learn how it tackles the root...
FDA Week: New blood test for Alzheimer's disease approved. See how Elecsys pTau217 helps identify amyloid pathology in adults 55...
Botox migraine therapy is gaining attention as it shows relief for migraine and spasticity, providing a targeted alternative to systemic...
FDA approval of Avulux migraine lenses offers an over‑the‑counter solution to reduce photophobia for migraine sufferers aged 12+, complementing existing...
Gene therapy MPS II stalls as the FDA places a clinical hold on RGX-121 after MRI scans revealed spinal abnormalities,...
Factor XIa inhibitors are emerging as a promising antithrombotic option to reduce recurrent strokes, offering better protection than aspirin or...
FDA approves new treatments for brain disorders, including Tourette syndrome, with priority review for ecopipam drug application.